 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Neurocrine Biosciences, Inc. (NBIX) discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. 
The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia.
The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor.
The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia.
Shares have formed a bullish flag following the company's latest quarterly results. On August 4th, Neurocrine Bioscienc reported a 2nd Quarter June 2022 loss of $0.18 per share on revenue of $378.2 million. The consensus earnings estimate was $0.56 per share on revenue of $340.2 million. Revenue grew 30.9% on a year-over-year basis. The company raised the FY22 Ingrezza sales outlook to $1.35 billion - $1.4 billion, higher than the previous expectations of $1.25 billion. Higher share prices are expected.
Entry Point: $104.00
Trading Range: $71.875 to $109.26
Stop Loss: $99.00
Target Price: $115.00
